Related Experiment Video
Updated: Aug 19, 2026

Development of Obliterative Bronchiolitis in a Murine Model of Orthotopic Lung Transplantation
Published on: July 10, 2012
Bronchiolitis in infants
1University of Pennsylvania School of Medicine, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania 19104, USA. panitch@email.chop.edu
Insights
Bronchiolitis, a common infant wheezing illness caused by Respiratory Syncytial Virus (RSV), lacks proven treatments beyond supportive care. Research aims to find effective, safe methods to manage acute symptoms and prevent long-term airway issues.
Area of Science:
- Pediatrics
- Infectious Diseases
- Pulmonology
Background:
- Bronchiolitis is a frequent cause of infant wheezing, predominantly caused by Respiratory Syncytial Virus (RSV).
- RSV infections lead to over 125,000 US hospitalizations annually.
- Current treatment for infant bronchiolitis beyond supportive care is controversial due to limited evidence of pharmacologic agent efficacy.
Purpose of the Study:
- To investigate the safest and most cost-effective treatments for infant bronchiolitis.
- To address both acute obstructive symptoms and the prevention of recurrent airway obstruction.
- To explore novel therapeutic strategies based on understanding RSV pathogenesis and virus-host interactions.
Main Methods:
- The abstract does not specify the methods used in the study.
- Focus is on the ongoing search for effective treatments and understanding disease mechanisms.
- Literature review and clinical practice observations are implied.
Main Results:
- The abstract does not present specific results.
- Highlights the controversy surrounding current treatment modalities.
- Emphasizes the need for evidence-based interventions.
Conclusions:
- Effective treatments for infant bronchiolitis are still under investigation.
- Understanding RSV pathogenesis may lead to future therapies.
- Preventing recurrent wheezing and asthma post-bronchiolitis is a key research goal.
Abstract:
Bronchiolitis is a common cause of wheezing among infants. Respiratory syncytial virus (RSV) is the most common infectious agent to cause bronchiolitis, and RSV infection accounts for more than 125,000 hospitalizations per year in the United States. Beyond supportive measures, the care of infants with bronchiolitis remains controversial. Practitioners continue to treat infants with a variety of pharmacologic agents, despite limited evidence of their efficacy. Investigators continue to search for the safest and most cost-effective methods to treat infants with bronchiolitis, not only to overcome obstructive symptoms during the acute illness, but also to prevent recurrent symptoms of airway obstruction that occur in some children for years after their initial episode of bronchiolitis. Improved understanding of the pathogenesis of RSV infection and of virus-host interactions may one day lead to the development of agents that alter the initial inflammatory response and strategies that help prevent recurrent episodes of wheezing and the development of asthma after acute bronchiolitis.
Related Concept Videos
Breathing
Pulmonary Cycle: Exhalation
Pneumonia I: Introduction
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
Respiratory Syncytial Virus Disease
Chronic Obstructive Pulmonary Disease III: Chronic Bronchitis Features
Pneumonia I: Introduction

